文献速递临床试验与 GCP

LIFE-MET试验:生活方式干预和/或二甲双胍治疗对超重早期青春期女孩青春期进展的影响:一项随机安慰剂对照试验的研究方案

The LIFE-MET trial: effect of insulin sensitization on pubertal progression following lifestyle intervention and/or treatment with metformin in girls with early puberty and overweight: study protocol for a randomized, placebo-controlled trial.
PubMed 文献 · Trials · 2025-11-25

LIFE-MET是一项随机、安慰剂对照、四臂、多中心试验,纳入80名超重且青春期提前的女孩,随机分配至二甲双胍+生活方式干预组(N=20)、单用二甲双胍组(N=20)、安慰剂+生活方式干预组(N=20)或单用安慰剂组(N=20),干预6个月并随访6个月。主要结局为基線至12个月骨龄变化,作为青春期进展标志。

要点

  • 纳入80名超重且青春期提前的女孩,随机分为四组,每组20人。
  • 主要结局为基線至12个月骨龄变化,作为青春期进展标志。
  • 干预6个月,随访6个月,二甲双胍分配采用双盲。

核心结论

  • LIFE-MET试验是据作者所知首个结合生活方式干预(包括在线、虚拟现实训练)与二甲双胍和/或安慰剂药物干预的随机对照试验。
  • 作者预期该干预对青春期进展、每日体力活动水平和身体成分均有有益影响。
  • 更健康的身体成分可能对与青春期提前相关的长期共病产生有益影响。

研究设计与样本

  • LIFE-MET是一项随机、安慰剂对照、四臂、多中心试验,纳入80名超重且青春期提前的女孩(n=80)。
  • 二甲双胍或安慰剂分配采用双盲。
  • 符合条件女孩随机分配至四个研究组之一:二甲双胍+生活方式干预组(N=20)、单用二甲双胍组(N=20)、安慰剂+生活方式干预组(N=20)、单用安慰剂组(N=20)。
  • 干预期为6个月,额外随访6个月。

主要发现

  • 主要结局为基線至12个月骨龄变化,作为青春期进展标志。
  • 次要结局包括身体成分、Tanner分期、体能水平、性激素、胰岛素抵抗和月经初潮年龄的变化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Puberty in girls is occurring earlier worldwide with a declining trend over the recent decades, resulting in increased attention on the accompanying risks of psychosocial challenges and adverse health outcomes for the affected girls. Diverse mechanisms have been proposed as mediators of the tendency for earlier pubertal maturation, including a shift toward a more sedentary lifestyle and changes in dietary habits leading to childhood obesity. Several studies have demonstrated a potential association between the rise in childhood obesity prevalence and the decline in the age at which puberty begins. Increased insulin resistance is thought to play a role in this connection, and previous studies indicated that improved insulin sensitivity following either treatment with metformin or weight loss could delay pubertal progression in girls with overweight. METHODS: LIFE-MET is a randomized, placebo-controlled, four-arm, multicenter trial of girls (n = 80) with overweight and early puberty. Allocation to metformin or placebo will be double-blinded. Eligible girls will be randomly assigned to one of the four study arms: Metformin + lifestyle intervention (N = 20), Metformin alone (N = 20), Placebo + lifestyle intervention (N = 20), Placebo alone (N = 20). The intervention period is 6 months with a follow-up after an additional 6 months. The primary outcome is the change in bone age from baseline to 12 months, as a marker of pubertal progression. Secondary outcomes include changes in body composition, Tanner stage, fitness level, sex hormones, insulin resistance, and age at menarche. DISCUSSION: New strategies not only for the treatment but also for the prevention of both overweight and early puberty are needed. The LIFE-MET trial is a randomized controlled trial with a combination of lifestyle intervention including online, virtual reality training and a pharmacological intervention consisting of metformin and/or placebo, to our knowledge the first of its kind. We expect that this intervention will have a beneficial effect on both pubertal progression, daily physical activity level, and body composition. Additionally, a healthier body composition may have beneficial effects on long-term co-morbidities related to early puberty. TRIAL REGISTRATION: Clinical Trial Information System (CTIS): 2024-511009-50-00. Approved 04/30/2024. https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2024-511009-50-00 .

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Laerkholm G, Thybo LAB, Rasmussen AB, et al. The LIFE-MET trial: effect of insulin sensitization on pubertal progression following lifestyle intervention and/or treatment with metformin in girls with early puberty and overweight: study protocol for a randomized, placebo-controlled trial. Trials. 2025. PMID: 41291865. doi:10.1186/s13063-025-09229-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。